微量白蛋白尿(MAU)是评价早期肾脏病变和全身内皮系统病变的敏感指标,且可作为肾功能不全和心血管疾病发病率及病死率的独立预测因子。将MAU应用于重症监护(ICU)患者具有理论上的依据。通过对MAU水平的检测,可评价ICU患者肾脏病变、心脑血管病变、急性肺损伤、全身炎性反应综合征、多器官功能障碍综合征等疾病严重程度并预测预后,以便尽早采取有针对性的干预措施以改善预后。 Microalbuminuria (MAU) is a sensitive measure of early renal disease and systemic endothelial disease and can be used as an independent predictor of morbidity and mortality of renal insufficiency and cardiovascular disease. There is a theoretical basis for applying MAU in intensive care (ICU) patients. Through the detection of MAU level, we can evaluate the severity of ICE patients such as kidney disease, cardiovascular and cerebrovascular disease, acute lung injury, systemic inflammatory response syndrome, multiple organ dysfunction syndrome and predict the prognosis so as to take the targeted Interventions to improve the prognosis.